RegulatoryCompany release

Erasca's pan-RAS glue ERAS-0015 wins FDA Fast Track for pancreatic cancer

🇺🇸 Erasca, Inc. (ERAS) · Thu 12 Nov 2026

The designation covers metastatic pancreatic adenocarcinoma, as Erasca reports $947.8M in cash at Q3 2026 after a July public offering of about $632.5M.

Erasca reported its third-quarter 2026 results on 12 November. The update included the news that the US Food and Drug Administration granted Fast Track Designation in August 2026 to ERAS-0015, the company's pan-RAS molecular glue, for metastatic pancreatic adenocarcinoma.

Erasca plans three trials in pancreatic and lung cancers that could potentially support registration. The summary available does not give details of the trial designs, patient populations, endpoints or timelines.

On the financial side, the company reported cash of $947.8M. This follows a public offering in July 2026 that raised roughly $632.5M. The source material available does not break down the offering further or set out expected cash runway.

Fast Track is an FDA programme intended to speed the development and review of drugs for serious conditions with unmet medical need. It allows more frequent interaction with the agency and can make a rolling submission of an application possible. It does not guarantee approval or alter the standards for demonstrating safety and efficacy.

What it means for your team

  • Fast Track status for ERAS-0015 signals closer FDA dialogue and potential rolling submission, though it does not change evidentiary standards for approval.
  • Regulatory teams tracking RAS-targeted oncology should note three planned potentially registration-enabling trials across pancreatic and lung cancers; design details have not yet been disclosed in the material available.
  • The roughly $632.5M July offering and $947.8M cash position suggest the company is funded for a multi-trial programme, which is relevant for competitive and market-access planning.

Company's press release (SEC filing): Erasca, Inc. ↗

Article written by VigiEye from the official source (Erasca, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Regulatory All →